金吾财讯 | 药明康德(02359)公告，公司通过间接控股子公司累计出售药明合联(02268)8600万股股票，约占药明合联当前总股本的7.17%，累计成交金额约24.26亿港元，占公司最近一期经审计归属母公司股东净资产的4.07%。经初步核算，过去十二个月内公司出售药明合联股票累计实现的投资收益为人民币20.16亿元，占公司最近一期经审计归属母公司股东净利润的比例超过10%，其中影响公司2024年度当期净利润约为人民币7.2亿元，影响公司2025年度当期净利润约为人民币12.97亿元。
公司通过出售上述股票资产所获得的现金收益，将用于加速推进全球产能及能力建设，吸引并保留优秀人才，持续强化公司独特的一体化CRDMO业务模式，从而高效满足全球客户和患者日益增长且不断变化的需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.